[go: up one dir, main page]

NO20045153L - Stabilt, fast medisinpreparat for oral administrasjon - Google Patents

Stabilt, fast medisinpreparat for oral administrasjon

Info

Publication number
NO20045153L
NO20045153L NO20045153A NO20045153A NO20045153L NO 20045153 L NO20045153 L NO 20045153L NO 20045153 A NO20045153 A NO 20045153A NO 20045153 A NO20045153 A NO 20045153A NO 20045153 L NO20045153 L NO 20045153L
Authority
NO
Norway
Prior art keywords
ramosetron
ester
pharmaceutically acceptable
acid
acceptable salt
Prior art date
Application number
NO20045153A
Other languages
English (en)
Norwegian (no)
Inventor
Katsuhiro Masaki
Akio Sugihara
Takehiko Yasuji
Akito Nishida
Akira Niwa
Yutaka Atsuta
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20045153L publication Critical patent/NO20045153L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20045153A 2003-01-31 2004-11-25 Stabilt, fast medisinpreparat for oral administrasjon NO20045153L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003023500 2003-01-31
PCT/JP2004/000896 WO2004066998A1 (fr) 2003-01-31 2004-01-30 Composition medicinale solide, stable, d'administration par voie orale

Publications (1)

Publication Number Publication Date
NO20045153L true NO20045153L (no) 2005-02-04

Family

ID=32820728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045153A NO20045153L (no) 2003-01-31 2004-11-25 Stabilt, fast medisinpreparat for oral administrasjon

Country Status (21)

Country Link
US (1) US7794748B2 (fr)
EP (1) EP1588707B1 (fr)
JP (1) JP3689104B2 (fr)
KR (1) KR100633836B1 (fr)
CN (1) CN100379416C (fr)
AT (1) ATE420638T1 (fr)
AU (1) AU2004208617B2 (fr)
BR (1) BRPI0405221A (fr)
CA (1) CA2488422C (fr)
DE (1) DE602004019049D1 (fr)
DK (1) DK1588707T3 (fr)
ES (1) ES2319292T3 (fr)
IL (1) IL165371A (fr)
MX (1) MXPA04012462A (fr)
NO (1) NO20045153L (fr)
NZ (1) NZ537448A (fr)
PL (1) PL375181A1 (fr)
PT (1) PT1588707E (fr)
RU (1) RU2284819C2 (fr)
WO (1) WO2004066998A1 (fr)
ZA (2) ZA200409537B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7358270B2 (en) * 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
MX2009001429A (es) * 2006-08-10 2009-02-17 Takeda Pharmaceutical Composicion farmaceutica.
CN101516367A (zh) * 2006-09-15 2009-08-26 安斯泰来制药有限公司 对光稳定的雷莫司琼的固态医药组合物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
EP2328910B1 (fr) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
BR112012025344B1 (pt) * 2010-04-09 2021-10-13 Unilever Ip Holdings B.V. Composição para cuidados orais
BR112013015085A8 (pt) * 2010-12-16 2018-04-03 Univ Texas Composição farmacêutica, método para preparar uma composição, e, uso de composição
MX380805B (es) 2011-04-28 2025-03-12 Univ Texas Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
US10561628B2 (en) 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
BR112017019920B1 (pt) * 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
CN106937946B (zh) * 2016-01-05 2020-05-12 山东诚创医药技术开发有限公司 盐酸雷莫司琼泡腾片及其制备方法
CN107224430A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 一种含盐酸雷莫司琼的药物组合物
KR102349971B1 (ko) * 2016-04-27 2022-01-12 주식회사 엘지생활건강 폴리다틴 또는 이의 약학적으로 허용 가능한 염의 광 안정화용 조성물
BR112021001008A2 (pt) 2018-07-30 2021-04-20 Daiichi Sankyo Company, Limited comprimido de fármaco

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759081A (en) * 1954-04-15 1956-10-10 John Holroyd And Company Ltd Improvements relating to machines for the production of coated tablets and the like
US4067974A (en) * 1976-01-21 1978-01-10 The Purdue Frederick Company Stabilized solid form choline salicylate compositions
GB8629567D0 (en) * 1986-12-10 1987-01-21 Boots Co Plc Therapeutic agents
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
US5344927A (en) * 1989-02-02 1994-09-06 Yamanouchi Pharmaceutical Co., Ltd. Tetrahydrobenzimidazole derivatives and pharmaceutical compositions containing same
US5107887A (en) 1990-12-03 1992-04-28 The Aro Corporation High pressure fluid regulator
JPH0565226A (ja) * 1991-09-10 1993-03-19 Taisho Pharmaceut Co Ltd アミノアルキルピリジルオキシ誘導体の安定化組成物
DK0948965T3 (da) 1997-07-11 2004-07-05 Toray Industries Stabile medicinske præparater indeholdende 4,5-epoxymorphinanderivater
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
KR100571613B1 (ko) * 1997-10-20 2006-04-17 다이닛본 스미토모 세이야꾸 가부시끼가이샤 안정화 의약 조성물
HU229295B1 (en) * 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
HUP0202645A3 (en) 1999-08-09 2004-06-28 Pharmacia & Upjohn Spa Fornulations for parenteral use of estramustine phosphate and albumin
DE19941997A1 (de) * 1999-09-02 2001-03-08 Gunther Meinhardt Voss Verfahren und Vorrichtung zur Herstellung einer Tablette o. dgl.
MXPA03000520A (es) * 2000-07-17 2003-10-06 Yamanouchi Pharma Co Ltd Composicion farmaceutica mejorada en absorbabilidad peroral..
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
ATE482692T1 (de) * 2001-07-27 2010-10-15 Astellas Pharma Inc Zusammensetzung enthaltend feine körner mit verzögerter freisetzung für in der mundhöhle schnell zerfallende tabletten
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20030143548A1 (en) 2002-01-28 2003-07-31 Camilleri Michael L. Predicting patient responsiveness to serotonergic therapy
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7358270B2 (en) * 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome

Also Published As

Publication number Publication date
BRPI0405221A (pt) 2005-03-15
ATE420638T1 (de) 2009-01-15
MXPA04012462A (es) 2005-02-24
AU2004208617A1 (en) 2004-08-12
EP1588707A1 (fr) 2005-10-26
DE602004019049D1 (de) 2009-03-05
PT1588707E (pt) 2009-03-27
HK1084582A1 (zh) 2006-08-04
ZA200506503B (en) 2006-12-27
DK1588707T3 (da) 2009-03-09
CA2488422C (fr) 2008-08-19
JP3689104B2 (ja) 2005-08-31
ZA200409537B (en) 2006-10-25
KR100633836B1 (ko) 2006-10-13
KR20050044772A (ko) 2005-05-12
CN100379416C (zh) 2008-04-09
RU2004136181A (ru) 2005-08-10
RU2284819C2 (ru) 2006-10-10
NZ537448A (en) 2008-06-30
AU2004208617B2 (en) 2007-09-13
US20050026981A1 (en) 2005-02-03
EP1588707A4 (fr) 2006-03-15
CN1723021A (zh) 2006-01-18
CA2488422A1 (fr) 2004-08-12
JPWO2004066998A1 (ja) 2006-05-18
AU2004208617A2 (en) 2004-08-12
ES2319292T3 (es) 2009-05-06
EP1588707B1 (fr) 2009-01-14
IL165371A (en) 2009-08-03
WO2004066998A1 (fr) 2004-08-12
US7794748B2 (en) 2010-09-14
IL165371A0 (en) 2006-01-15
PL375181A1 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20045153L (no) Stabilt, fast medisinpreparat for oral administrasjon
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
ATE500818T1 (de) Kalziumatorvastatin enthaltende arzneiformulierung
BR0315580A (pt) Derivados de metileno uréia
HU224964B1 (en) Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
EA200702416A1 (ru) Фармацевтическая композиция, содержащая симвастатин и эзетимиб
JP2006520346A (ja) 制御放出システム
SE9901573D0 (sv) New compounds
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
ES2901706T3 (es) Composiciones de ketoprofeno de acción prolongada
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP2233133A1 (fr) Compositions stables comprenant de Rosuvastatine
ES2378091T3 (es) Composiciones farmacéuticas que contienen leflunomida
PT1179342E (pt) Composicoes medicinais de libertacao imediata para utilizacao oral
NO323556B1 (no) Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter.
WO2003070153A3 (fr) Compositions pharmaceutiques stabilisees d'halofuginone et d'autres derives de quinazolinone
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
JP2009538822A (ja) 静脈におけるウイルスの治療
US20120283325A1 (en) Excipient compatibility with ezatiostat
WO2014195900A2 (fr) Compositions pharmaceutiques à administration par voie orale destinées à être utilisées dans les dyslipidémies
EP1466909A4 (fr) Derives d'acide halogenobenzylaminopropionique
JPH107570A (ja) パーキンソン病予防・治療剤
CY1114106T1 (el) Σταθερες φαρμακευτικες συνθεσεις που περιεχουν 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
HRP20090592T1 (hr) Izoksazolni derivat za ublažavanje neuropatskih bolova

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application